Business Associate Agreement Janssen

Janssen Pharmaceuticals has signed a licensing and cooperation agreement with Arrowhead Pharmaceuticals for the development and commercialization of a new therapeutic candidate, ARO-HBV. The companies have also entered into a separate research cooperation and options agreement, including up to three other RNAi therapeutics against new targets selected by Janssen. Arrowhead is also entitled to milestone payments of up to $1.6 billion for the ARO-HBV license agreement and nearly $1.9 billion in option and milestone payments under the second agreement. . For more information about these programs, please call your Janssen CarePath patients at 877-CarePath (877-227-3728) Monday through Friday from 8:00 a.m. to 8:00 p.m. ET and speak to a Janssen CarePath CarePath coordinator. Treatment assistance to help your patients get informed and receive the prescribed treatment. Start today with your legitimate patients…